This content is not available in your region

Biogen first-quarter profit rises 20% on Spinraza strength

Biogen first-quarter profit rises 20% on Spinraza strength
FILE PHOTO: A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian Snyder/File Photo   -   Copyright  Brian Snyder(Reuters)
Text size Aa Aa

(Reuters) – Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday, driven by higher sales of its muscle disease treatment Spinraza.

Spinal muscular atrophy treatment Spinraza brought in $518 million in the quarter, beating Refinitiv IBES estimates of $486.4 million (£376.1 million).

Multiple sclerosis drug Tecfidera, which brought in $999 million in the quarter, missed estimates, and faces several challenges to its intellectual property, which is key to shielding the blockbuster drug from generic competition.

Net income attributable to the company rose to $1.41 billion, or $7.15 per share, in the quarter ended March 31, from $1.17 billion, or $5.54 per share, a year earlier. (

On an adjusted basis, the company earned $6.98 per share.

Total revenue rose to $3.49 billion, beating estimates of $3.39 billion.

(Reporting by Manojna Maddipatla and Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.